AbbVie is a top dividend stock with a strong business, boasting 54 consecutive payout increases and $15.8 billion in third-quarter revenue. Eli Lilly is rapidly growing, with third-quarter revenue of $17.6 billion and investments in diversifying therapeutic areas like oncology. Despite challenges, Intuitive Surgical remains a buy with its wide economic moat, 10,763 da Vinci systems installed, and potential for revenue growth from label expansions. Overall, healthcare stocks like AbbVie, Eli Lilly, and Intuitive Surgical present attractive investment opportunities for 2026.

Read more at Nasdaq, Inc.: My Top 3 Healthcare Stocks to Buy in 2026